TY - JOUR
T1 - Hereditary angiodema
T2 - A current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema
AU - Bowen, Tom
AU - Cicardi, Marco
AU - Bork, Konrad
AU - Zuraw, Bruce
AU - Frank, Mike
AU - Ritchie, Bruce
AU - Farkas, Henriette
AU - Varga, Lilian
AU - Zingale, Lorenza C.
AU - Binkley, Karen
AU - Wagner, Eric
AU - Adomaitis, Peggy
AU - Brosz, Kristylea
AU - Burnham, Jeanne
AU - Warrington, Richard
AU - Kalicinsky, Chrystyna
AU - Mace, Sean
AU - McCusker, Christine
AU - Schellenberg, Robert
AU - Celeste, Lucia
AU - Hebert, Jacques
AU - Valentine, Karen
AU - Poon, Man Chiu
AU - Serushago, Bazir
AU - Neurath, Doris
AU - Yang, William
AU - Lacuesta, Gina
AU - Issekutz, Andrew
AU - Hamed, Azza
AU - Kamra, Palinder
AU - Dean, John
AU - Kanani, Amin
AU - Stark, Donald
AU - Rivard, Georges Etienne
AU - Leith, Eric
AU - Tsai, Ellie
AU - Waserman, Susan
AU - Keith, Paul K.
AU - Page, David
AU - Marchesin, Silvia
AU - Longhurst, Hilary J.
AU - Kreuz, Wolfhart
AU - Rusicke, Eva
AU - Martinez-Saguer, Inmaculada
AU - Aygören-Pürsün, Emel
AU - Harmat, George
AU - Füst, George
AU - Li, Henry
AU - Bouillet, Laurence
AU - Caballero, Teresa
AU - Moldovan, Dumitru
AU - Späth, Peter J.
AU - Smith-Foltz, Sara
AU - Nagy, Istvan
AU - Nielsen, Erik W.
AU - Bucher, Christoph
AU - Nordenfeit, Patrik
AU - Zhi, Yu Xiang
PY - 2008/1
Y1 - 2008/1
N2 - Background: We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004. Objective: To ensure that this consensus remains current. Methods: In collaboration with the Canadian Network of Rare Blood Disorder Organizations, we held the second Canadian Consensus discussion with our international colleagues in Toronto, Ontario, on February 3, 2006, and reviewed its content at the Fifth C1 Inhibitor Deficiency Workshop in Budapest on June 2, 2007. Papers were presented by international investigators, and this consensus algorithm approach resulted. Results: This consensus algorithm outlines the approach recommended for the diagnosis, therapy, and management of HAE, which was agreed on by the authors of this report. This document is only a consensus algorithm approach and continues to require validation. As such, participants agreed to make this a living 2007 algorithm, a work in progress, and to review its content at future international HAE meetings. Conclusions: There is a paucity of double-blind, placebo-controlled trials on the treatment of HAE, making levels of evidence to support the algorithm less than optimal. Controlled trials currently under way will provide further insight into the management of HAE. As with our Canadian 2003 Consensus, this 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of HAE was formed through the meeting and agreement of patient care professionals along with patient group representatives and individual patients.
AB - Background: We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004. Objective: To ensure that this consensus remains current. Methods: In collaboration with the Canadian Network of Rare Blood Disorder Organizations, we held the second Canadian Consensus discussion with our international colleagues in Toronto, Ontario, on February 3, 2006, and reviewed its content at the Fifth C1 Inhibitor Deficiency Workshop in Budapest on June 2, 2007. Papers were presented by international investigators, and this consensus algorithm approach resulted. Results: This consensus algorithm outlines the approach recommended for the diagnosis, therapy, and management of HAE, which was agreed on by the authors of this report. This document is only a consensus algorithm approach and continues to require validation. As such, participants agreed to make this a living 2007 algorithm, a work in progress, and to review its content at future international HAE meetings. Conclusions: There is a paucity of double-blind, placebo-controlled trials on the treatment of HAE, making levels of evidence to support the algorithm less than optimal. Controlled trials currently under way will provide further insight into the management of HAE. As with our Canadian 2003 Consensus, this 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of HAE was formed through the meeting and agreement of patient care professionals along with patient group representatives and individual patients.
UR - http://www.scopus.com/inward/record.url?scp=38049005317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38049005317&partnerID=8YFLogxK
U2 - 10.1016/S1081-1206(10)60584-4
DO - 10.1016/S1081-1206(10)60584-4
M3 - Article
C2 - 18220150
AN - SCOPUS:38049005317
SN - 1081-1206
VL - 100
SP - S30-S40
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 1 SUPPL. 2
ER -